With the support of the Equity Council, NCI launched EIAP in late 2021 to facilitate the advancement of scientists from diverse backgrounds to become independent investigators. The cancer research enterprise needs a continuous flow of talent through the research career pipeline to thrive. One critical juncture is the transition from junior investigator to independent investigator. Each year, EIAP supports the professional and career development of a cohort of eligible and qualified Early Stage Investigators and New Investigators from institutions across the country.
The EIAP aims to:
- Enhance professional skills;
- Guide preparation of an R01 grant application;
- Provide access to a mentoring and peer network; and
- Grow a community of emerging independent investigators from diverse backgrounds.
This year Early Investigator Advancement Program (EIAP) has extended its deadline — the program will now accept applications until *December 1, 2022.* The target start date will be March 1, 2023.
Potential applicants should visit the EIAP webpage to learn about the first cohort and access information about eligibility, application instructions, and the pre-application webinar.
NCI values diversity and particularly encourages applicants from populations underrepresented in the biomedical sciences, as noted in the Notice of NIH’s Interest in Diversity (NOT-OD-20-031).
Contact: Drs. Samson Gebreab and Maria Jamela (Jay) Revilleza, EIAP@nih.gov
The Early Investigator Advancement Program is funded by the NCI Equity and Inclusion Program.
Early Investigator Advancement Program (EIAP) was originally published by the National Cancer Institute.